The Efficacy and Safety of Padexol(R) (Paclitaxel) and Cisplatin for Treating Advanced Non-small Cell Lung Cancer.
- Author:
Hoon Kyo KIM
1
;
Jun Suk KIM
;
Hun Mo RYOO
;
Dong Gun SHIN
;
Byoung Young SHIM
;
Kyong Hwa PARK
;
Sung Hwa BAE
;
Chi Hong KIM
Author Information
1. Department of Internal Medicine, St. Vincent's Hospital, The Catholic Unviersity of Korea, Korea. kimhoonkyo@yahoo.co.kr
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Non-small cell lung cancer;
Chemotherapy;
Padexol(R);
Cisplatin
- MeSH:
Anemia;
Anorexia;
Carcinoma, Non-Small-Cell Lung*;
Cisplatin*;
Drug Therapy;
Drug Therapy, Combination;
Febrile Neutropenia;
Follow-Up Studies;
Humans;
Infusions, Intravenous;
Myalgia;
Nausea;
Neutropenia;
Paclitaxel;
Premedication;
Research Personnel
- From:Cancer Research and Treatment
2006;38(2):66-70
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The authors conducted a multicenter study to evaluate the efficacy and safety of combination chemotherapy with Padexol(R) and cisplatin for treating patients with advanced non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: From November 2003 to April 2005, 42 chemo-naive patients with advanced NSCLC were enrolled into this study from 4 hospitals. The treatment consisted of Padexol(R) 175 mg/m2 as a 3-hr infusion, and this was followed by cisplatin 75 mg/m2 administered as an intravenous infusion with standard premedication. The treatment was repeated every 3 weeks. RESULTS: Among the 42 patients (pts), 33 pts were evaluable for response. On the per protocol analysis, 1 patient (pt) (3.0%) achieved complete response (CR), 17 pts (51.5%) achieved partial response (PR), 6 pts (18.2%) achieved stable disease (SD), and 9 pts (27.3%) progressed; therefore, the overall response rate was 54.6% (95% CI: 37.6~71.5%). On the intention-to-treat analysis, 1 pt (2.4%) achieved CR, 18 pts (42.9%) achieved PR, 11 pts (26.2%) achieved SD, and 9 pts (21.4%) progressed; therefore, the overall response rate was 45.2% (95% CI: 30.2~60.3%). The response, as evaluated by the investigators, was independently reviewed by 2 external radiologists and it was as follows; 13 PR (43.3%), 14 SD (46.7%) and 3 progressive disease (10%). The median duration of response was 5.9 months. The median follow-up duration was 10.3 months (range: 1.3 to 22.1 months). The median time to progression was 5.8 months (95% CI: 4.7 to 7.4 months). The median survival time on the intention-to-treat analysis was 10.5 months (95% CI: 8.1 to 18.8 months). The most common grade 3 or 4 hematologic toxicities were neutropenia (26/180 cycles, 14.4%), anemia (7/180 cycles, 3.9%) and febrile neutropenia (2/180 cycles, 1.1%). The most frequent grade 3 or 4 non-hematologic toxicities were nausea (14/42 patients, 14.3%), anorexia (3/42 patients, 7.1%) and myalgia (3/42 patients, 7.1%). CONCLUSION: The authors observed that Padexol(R) was as good as the other paclitaxel (Taxol(R) or Genexol(R)) formulations when combined with cisplatin for treating patients with advanced NSCLC.
